Skip to main content

From the Helm: Clarity Pharmaceuticals Executive Chairman, Alan Taylor

Bell Direct
May 24, 2024

Embark on a journey of discovery with Dr. Alan as he unveils the cutting-edge breakthroughs of Clarity Pharma, a pioneering force in the relentless fight against cancer through next-generation radiopharmaceuticals. In this instalment of our From the helm series, Bell Direct’s Grady Wulff speaks to Clarity Pharmaceuticals (ASX:CU6) Executive Chairman, Dr Alan Taylor.

Clarity Pharmaceuticals specialises in the development of Targeted Copper Theragnostic for the imaging and treatment of selected cancers. Clarity Pharma has an extensive program of clinical development for imaging and cancer therapy with a series of important data readouts over the next few years.

In this video Dr. Alan discusses:

  • (1:27) an overview of the company, including their 7 clinical trials
  • (3:35) the promising results from their SECuRE trial
  • (11:55) why the radiopharmaceutical market is booming
  • (14:47) why Clarity Pharma could be an investment opportunity.

Market Update

Julia Lee
April 28, 2016

Under the Radar Report: Blue sky stocks

Richard Hemming
April 22, 2016

Three Quintessential Stocks

Bell Direct
April 13, 2016

Bell Potter Yield Stocks

Bell Direct
April 12, 2016

Market Open

Julia Lee
April 11, 2016

Small cap CEO interview: CV Check

Bell Direct
March 23, 2016

Market Update 14 March 2016

Julia Lee
March 14, 2016

Bell Potter banks march

Bell Direct
March 11, 2016

Portfolio Strategy Builder

Bell Direct
March 7, 2016